BRPI0916703A2 - usos de um polipeptídeo, e de um polinucleotídeo, e, composição - Google Patents

Info

Publication number

BRPI0916703A2

BRPI0916703A2 BRPI0916703A BRPI0916703A BRPI0916703A2 BR PI0916703 A2 BRPI0916703 A2 BR PI0916703A2 BR PI0916703 A BRPI0916703 A BR PI0916703A BR PI0916703 A BRPI0916703 A BR PI0916703A BR PI0916703 A2 BRPI0916703 A2 BR PI0916703A2

Authority

BR

Brazil

Prior art keywords

polypeptide

rv3616c

protein sequence

sequence

tuberculosis

Prior art date

2008-07-25

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 399
• 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 345
• 229920001184 polypeptide Polymers 0.000 title claims abstract description 331
• 239000002157 polynucleotide Substances 0.000 title claims abstract description 138
• 108091033319 polynucleotide Proteins 0.000 title claims abstract description 138
• 102000040430 polynucleotide Human genes 0.000 title claims abstract description 138
• 239000000203 mixture Substances 0.000 title claims abstract description 116
• -1 and Substances 0.000 title abstract description 23
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 207
• 238000000034 method Methods 0.000 claims abstract description 145
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 128
• 230000002163 immunogen Effects 0.000 claims abstract description 98
• 239000012634 fragment Substances 0.000 claims abstract description 90
• 238000011282 treatment Methods 0.000 claims abstract description 54
• 108020001507 fusion proteins Proteins 0.000 claims abstract description 49
• 102000037865 fusion proteins Human genes 0.000 claims abstract description 48
• 230000002265 prevention Effects 0.000 claims abstract description 43
• 206010065048 Latent tuberculosis Diseases 0.000 claims abstract description 26
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
• 101100445599 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) espA gene Proteins 0.000 claims description 204
• 201000008827 tuberculosis Diseases 0.000 claims description 169
• 108091007433 antigens Proteins 0.000 claims description 118
• 102000036639 antigens Human genes 0.000 claims description 118
• 239000000427 antigen Substances 0.000 claims description 116
• 241000282414 Homo sapiens Species 0.000 claims description 97
• 208000015181 infectious disease Diseases 0.000 claims description 72
• 150000007523 nucleic acids Chemical group 0.000 claims description 70
• 239000002671 adjuvant Substances 0.000 claims description 43
• 239000003814 drug Substances 0.000 claims description 39
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 35
• 230000005867 T cell response Effects 0.000 claims description 33
• 229940079593 drug Drugs 0.000 claims description 32
• 125000003729 nucleotide group Chemical group 0.000 claims description 28
• 238000004519 manufacturing process Methods 0.000 claims description 27
• 239000002773 nucleotide Substances 0.000 claims description 27
• 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 26
• 230000028993 immune response Effects 0.000 claims description 26
• 125000000539 amino acid group Chemical group 0.000 claims description 20
• 230000007420 reactivation Effects 0.000 claims description 19
• 210000004369 blood Anatomy 0.000 claims description 17
• 239000008280 blood Substances 0.000 claims description 17
• 239000002246 antineoplastic agent Substances 0.000 claims description 13
• 229940127089 cytotoxic agent Drugs 0.000 claims description 13
• 241000193830 Bacillus <bacterium> Species 0.000 claims description 12
• 238000009007 Diagnostic Kit Methods 0.000 claims description 11
• 239000003623 enhancer Substances 0.000 claims description 9
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 9
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
• 208000036981 active tuberculosis Diseases 0.000 claims description 8
• 230000036755 cellular response Effects 0.000 claims description 8
• 230000000295 complement effect Effects 0.000 claims description 8
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
• 229960003350 isoniazid Drugs 0.000 claims description 6
• QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 6
• 229960001225 rifampicin Drugs 0.000 claims description 6
• 241000124008 Mammalia Species 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 230000015788 innate immune response Effects 0.000 claims description 3
• 210000004927 skin cell Anatomy 0.000 claims description 2
• 230000036457 multidrug resistance Effects 0.000 claims 1
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
• 210000004027 cell Anatomy 0.000 description 225
• 235000018102 proteins Nutrition 0.000 description 108
• 235000001014 amino acid Nutrition 0.000 description 68
• 230000014509 gene expression Effects 0.000 description 66
• 210000001744 T-lymphocyte Anatomy 0.000 description 65
• 229940024606 amino acid Drugs 0.000 description 65
• 150000001413 amino acids Chemical class 0.000 description 63
• 239000013598 vector Substances 0.000 description 58
• 108020004414 DNA Proteins 0.000 description 47
• 102000039446 nucleic acids Human genes 0.000 description 46
• 108020004707 nucleic acids Proteins 0.000 description 46
• 230000004044 response Effects 0.000 description 42
• 241000701161 unidentified adenovirus Species 0.000 description 41
• 102000004127 Cytokines Human genes 0.000 description 40
• 108090000695 Cytokines Proteins 0.000 description 40
• 239000002502 liposome Substances 0.000 description 40
• 238000009472 formulation Methods 0.000 description 35
• 238000012360 testing method Methods 0.000 description 30
• 230000003053 immunization Effects 0.000 description 28
• 238000002649 immunization Methods 0.000 description 28
• 108010074328 Interferon-gamma Proteins 0.000 description 27
• 241000699670 Mus sp. Species 0.000 description 27
• 241000700605 Viruses Species 0.000 description 27
• 238000000338 in vitro Methods 0.000 description 25
• 150000001875 compounds Chemical class 0.000 description 24
• 230000004927 fusion Effects 0.000 description 24
• 102100037850 Interferon gamma Human genes 0.000 description 23
• 239000013604 expression vector Substances 0.000 description 23
• 239000000523 sample Substances 0.000 description 23
• 230000003612 virological effect Effects 0.000 description 23
• 229960005486 vaccine Drugs 0.000 description 21
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 20
• 239000002299 complementary DNA Substances 0.000 description 20
• 210000004443 dendritic cell Anatomy 0.000 description 20
• 238000009396 hybridization Methods 0.000 description 20
• 239000000243 solution Substances 0.000 description 20
• 201000010099 disease Diseases 0.000 description 19
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
• 239000002609 medium Substances 0.000 description 19
• 241000186359 Mycobacterium Species 0.000 description 18
• 238000004422 calculation algorithm Methods 0.000 description 18
• 210000004970 cd4 cell Anatomy 0.000 description 18
• 230000000694 effects Effects 0.000 description 18
• 238000003556 assay Methods 0.000 description 17
• 239000000126 substance Substances 0.000 description 17
• 108020004705 Codon Proteins 0.000 description 16
• 108010002350 Interleukin-2 Proteins 0.000 description 16
• 102000000588 Interleukin-2 Human genes 0.000 description 16
• 238000001727 in vivo Methods 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 15
• 125000003275 alpha amino acid group Chemical group 0.000 description 14
• 238000012217 deletion Methods 0.000 description 14
• 230000037430 deletion Effects 0.000 description 14
• 239000002245 particle Substances 0.000 description 14
• 238000000746 purification Methods 0.000 description 14
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 14
• 108091034117 Oligonucleotide Proteins 0.000 description 13
• 102100040247 Tumor necrosis factor Human genes 0.000 description 13
• 238000004458 analytical method Methods 0.000 description 13
• 238000009739 binding Methods 0.000 description 13
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 13
• 210000003491 skin Anatomy 0.000 description 13
• 238000006467 substitution reaction Methods 0.000 description 13
• 108700028369 Alleles Proteins 0.000 description 12
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
• 238000007792 addition Methods 0.000 description 12
• 230000003321 amplification Effects 0.000 description 12
• 230000027455 binding Effects 0.000 description 12
• 238000003199 nucleic acid amplification method Methods 0.000 description 12
• 241000894007 species Species 0.000 description 12
• 241000894006 Bacteria Species 0.000 description 11
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
• 210000000612 antigen-presenting cell Anatomy 0.000 description 11
• 239000003795 chemical substances by application Substances 0.000 description 11
• 238000003752 polymerase chain reaction Methods 0.000 description 11
• 230000035755 proliferation Effects 0.000 description 11
• 238000002255 vaccination Methods 0.000 description 11
• 238000002965 ELISA Methods 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 238000006243 chemical reaction Methods 0.000 description 10
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
• AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 10
• 230000002068 genetic effect Effects 0.000 description 10
• 230000036039 immunity Effects 0.000 description 10
• 230000010076 replication Effects 0.000 description 10
• 229930182490 saponin Natural products 0.000 description 10
• 235000017709 saponins Nutrition 0.000 description 10
• 150000007949 saponins Chemical class 0.000 description 10
• 208000024891 symptom Diseases 0.000 description 10
• 238000013519 translation Methods 0.000 description 10
• 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 9
• 230000015572 biosynthetic process Effects 0.000 description 9
• 230000002950 deficient Effects 0.000 description 9
• 238000001514 detection method Methods 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 9
• 125000005647 linker group Chemical group 0.000 description 9
• 210000002540 macrophage Anatomy 0.000 description 9
• 239000011159 matrix material Substances 0.000 description 9
• 239000013612 plasmid Substances 0.000 description 9
• 150000003839 salts Chemical class 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 238000013518 transcription Methods 0.000 description 9
• 230000035897 transcription Effects 0.000 description 9
• 239000003981 vehicle Substances 0.000 description 9
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 8
• 239000002253 acid Substances 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 230000005059 dormancy Effects 0.000 description 8
• 238000000684 flow cytometry Methods 0.000 description 8
• 239000001963 growth medium Substances 0.000 description 8
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
• 230000010354 integration Effects 0.000 description 8
• 239000007788 liquid Substances 0.000 description 8
• 239000003550 marker Substances 0.000 description 8
• 238000004806 packaging method and process Methods 0.000 description 8
• 239000012071 phase Substances 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 238000010561 standard procedure Methods 0.000 description 8
• 238000012546 transfer Methods 0.000 description 8
• 241001430294 unidentified retrovirus Species 0.000 description 8
• 101710166488 6 kDa early secretory antigenic target Proteins 0.000 description 7
• 238000011748 CB6F1 mouse Methods 0.000 description 7
• 241000282326 Felis catus Species 0.000 description 7
• 241000282412 Homo Species 0.000 description 7
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
• 230000006052 T cell proliferation Effects 0.000 description 7
• 239000004480 active ingredient Substances 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 238000003745 diagnosis Methods 0.000 description 7
• 230000005847 immunogenicity Effects 0.000 description 7
• 238000002347 injection Methods 0.000 description 7
• 239000007924 injection Substances 0.000 description 7
• 238000003780 insertion Methods 0.000 description 7
• 230000037431 insertion Effects 0.000 description 7
• 150000002632 lipids Chemical class 0.000 description 7
• 108020004999 messenger RNA Proteins 0.000 description 7
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 7
• 239000007764 o/w emulsion Substances 0.000 description 7
• 210000005259 peripheral blood Anatomy 0.000 description 7
• 239000011886 peripheral blood Substances 0.000 description 7
• 229920000642 polymer Polymers 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 229960005322 streptomycin Drugs 0.000 description 7
• 239000003826 tablet Substances 0.000 description 7
• 239000013603 viral vector Substances 0.000 description 7
• 108091026890 Coding region Proteins 0.000 description 6
• 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 6
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
• 150000007513 acids Chemical class 0.000 description 6
• 235000004279 alanine Nutrition 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
• 230000000763 evoking effect Effects 0.000 description 6
• 238000003018 immunoassay Methods 0.000 description 6
• 230000003308 immunostimulating effect Effects 0.000 description 6
• 230000001939 inductive effect Effects 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 239000000463 material Substances 0.000 description 6
• 239000012528 membrane Substances 0.000 description 6
• 239000004005 microsphere Substances 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 239000000843 powder Substances 0.000 description 6
• 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
• 230000001177 retroviral effect Effects 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 210000000952 spleen Anatomy 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 238000001890 transfection Methods 0.000 description 6
• IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 5
• 108090000565 Capsid Proteins Proteins 0.000 description 5
• 102100023321 Ceruloplasmin Human genes 0.000 description 5
• 241000196324 Embryophyta Species 0.000 description 5
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• 108010065805 Interleukin-12 Proteins 0.000 description 5
• 102000013462 Interleukin-12 Human genes 0.000 description 5
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
• 208000032420 Latent Infection Diseases 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• 241000699666 Mus <mouse, genus> Species 0.000 description 5
• 108010076504 Protein Sorting Signals Proteins 0.000 description 5
• 238000010521 absorption reaction Methods 0.000 description 5
• 229960003767 alanine Drugs 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 235000012000 cholesterol Nutrition 0.000 description 5
• 238000010367 cloning Methods 0.000 description 5
• 238000000576 coating method Methods 0.000 description 5
• 230000001186 cumulative effect Effects 0.000 description 5
• GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
• 230000001419 dependent effect Effects 0.000 description 5
• 239000006185 dispersion Substances 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 229960000285 ethambutol Drugs 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 239000003999 initiator Substances 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 238000002372 labelling Methods 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 210000004698 lymphocyte Anatomy 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 5
• 230000035772 mutation Effects 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 230000001717 pathogenic effect Effects 0.000 description 5
• 230000035699 permeability Effects 0.000 description 5
• 229920000056 polyoxyethylene ether Polymers 0.000 description 5
• 229920001282 polysaccharide Polymers 0.000 description 5
• 239000005017 polysaccharide Substances 0.000 description 5
• 150000004804 polysaccharides Chemical class 0.000 description 5
• 238000012545 processing Methods 0.000 description 5
• 229960005206 pyrazinamide Drugs 0.000 description 5
• IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 238000012552 review Methods 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 239000011732 tocopherol Substances 0.000 description 5
• 229960001295 tocopherol Drugs 0.000 description 5
• 229930003799 tocopherol Natural products 0.000 description 5
• 235000010384 tocopherol Nutrition 0.000 description 5
• 229960001005 tuberculin Drugs 0.000 description 5
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
• VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 4
• WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 108010065839 Capreomycin Proteins 0.000 description 4
• 102000053602 DNA Human genes 0.000 description 4
• 206010059866 Drug resistance Diseases 0.000 description 4
• 241000588724 Escherichia coli Species 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• 241000598171 Human adenovirus sp. Species 0.000 description 4
• 102000008070 Interferon-gamma Human genes 0.000 description 4
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
• 108010052285 Membrane Proteins Proteins 0.000 description 4
• 241000186366 Mycobacterium bovis Species 0.000 description 4
• 101100456232 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) mbtI gene Proteins 0.000 description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
• 108091081024 Start codon Proteins 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• 241000700647 Variola virus Species 0.000 description 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
• 125000000217 alkyl group Chemical group 0.000 description 4
• 229960004821 amikacin Drugs 0.000 description 4
• LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 4
• 229960004909 aminosalicylic acid Drugs 0.000 description 4
• 230000000692 anti-sense effect Effects 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 230000003115 biocidal effect Effects 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 239000001506 calcium phosphate Substances 0.000 description 4
• 229960004602 capreomycin Drugs 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 230000016396 cytokine production Effects 0.000 description 4
• 230000001086 cytosolic effect Effects 0.000 description 4
• 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 4
• 229960002001 ethionamide Drugs 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 238000013265 extended release Methods 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 238000005755 formation reaction Methods 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
• 235000011187 glycerol Nutrition 0.000 description 4
• 210000002443 helper t lymphocyte Anatomy 0.000 description 4
• 229960001438 immunostimulant agent Drugs 0.000 description 4
• 239000003022 immunostimulating agent Substances 0.000 description 4
• 238000002513 implantation Methods 0.000 description 4
• 230000002458 infectious effect Effects 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 229960000318 kanamycin Drugs 0.000 description 4
• 229930027917 kanamycin Natural products 0.000 description 4
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
• 229930182823 kanamycin A Natural products 0.000 description 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
• 230000021633 leukocyte mediated immunity Effects 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 210000004962 mammalian cell Anatomy 0.000 description 4
• 229930182817 methionine Natural products 0.000 description 4
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
• 244000005700 microbiome Species 0.000 description 4
• 239000011859 microparticle Substances 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 238000012544 monitoring process Methods 0.000 description 4
• 239000002088 nanocapsule Substances 0.000 description 4
• 150000003904 phospholipids Chemical class 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 238000004393 prognosis Methods 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 238000010186 staining Methods 0.000 description 4
• 238000007920 subcutaneous administration Methods 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 230000007704 transition Effects 0.000 description 4
• 208000030507 AIDS Diseases 0.000 description 3
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 108700010070 Codon Usage Proteins 0.000 description 3
• 241000759568 Corixa Species 0.000 description 3
• DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 3
• DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
• 230000004543 DNA replication Effects 0.000 description 3
• 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 3
• 101710088335 Diacylglycerol acyltransferase/mycolyltransferase Ag85A Proteins 0.000 description 3
• 108010013369 Enteropeptidase Proteins 0.000 description 3
• 102100029727 Enteropeptidase Human genes 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 108010070675 Glutathione transferase Proteins 0.000 description 3
• 239000004471 Glycine Substances 0.000 description 3
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
• 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 3
• 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 3
• 241001135569 Human adenovirus 5 Species 0.000 description 3
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
• 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 3
• 108010002616 Interleukin-5 Proteins 0.000 description 3
• 102000000743 Interleukin-5 Human genes 0.000 description 3
• 108091092195 Intron Proteins 0.000 description 3
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• 102000043129 MHC class I family Human genes 0.000 description 3
• 108091054437 MHC class I family Proteins 0.000 description 3
• 102000018697 Membrane Proteins Human genes 0.000 description 3
• 241000187644 Mycobacterium vaccae Species 0.000 description 3
• 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
• 101710182846 Polyhedrin Proteins 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 101710188053 Protein D Proteins 0.000 description 3
• 101710132893 Resolvase Proteins 0.000 description 3
• 108091028664 Ribonucleotide Proteins 0.000 description 3
• 241000723873 Tobacco mosaic virus Species 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 108020005202 Viral DNA Proteins 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
• 125000003277 amino group Chemical group 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 description 3
• 235000011010 calcium phosphates Nutrition 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000020411 cell activation Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 229960003405 ciprofloxacin Drugs 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 229960003077 cycloserine Drugs 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 238000002405 diagnostic procedure Methods 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
• 210000002919 epithelial cell Anatomy 0.000 description 3
• 108700004026 gag Genes Proteins 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000003494 hepatocyte Anatomy 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 239000004615 ingredient Substances 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 229940117681 interleukin-12 Drugs 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• 239000002324 mouth wash Substances 0.000 description 3
• 229940051866 mouthwash Drugs 0.000 description 3
• 239000010813 municipal solid waste Substances 0.000 description 3
• 239000013642 negative control Substances 0.000 description 3
• 230000008520 organization Effects 0.000 description 3
• 244000052769 pathogen Species 0.000 description 3
• 239000002831 pharmacologic agent Substances 0.000 description 3
• 229940051841 polyoxyethylene ether Drugs 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 230000001681 protective effect Effects 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 239000002336 ribonucleotide Substances 0.000 description 3
• 239000007787 solid Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
• 238000011144 upstream manufacturing Methods 0.000 description 3
• 210000002845 virion Anatomy 0.000 description 3
• HDTRYLNUVZCQOY-UHFFFAOYSA-N &alpha;-D-glucopyranosyl-&alpha;-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
• GMRQFYUYWCNGIN-UHFFFAOYSA-N 1,25-Dihydroxy-vitamin D3' Natural products C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2C1=CC=C1CC(O)CC(O)C1=C GMRQFYUYWCNGIN-UHFFFAOYSA-N 0.000 description 2
• BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
• GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 2
• 206010001258 Adenoviral infections Diseases 0.000 description 2
• 108700023418 Amidases Proteins 0.000 description 2
• 241000304886 Bacilli Species 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
• 108010029697 CD40 Ligand Proteins 0.000 description 2
• 101150013553 CD40 gene Proteins 0.000 description 2
• 102100032937 CD40 ligand Human genes 0.000 description 2
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 108010039939 Cell Wall Skeleton Proteins 0.000 description 2
• 241001227713 Chiron Species 0.000 description 2
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
• YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
• 108010074860 Factor Xa Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 108010024636 Glutathione Proteins 0.000 description 2
• 206010018691 Granuloma Diseases 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
• 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 2
• 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
• 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 2
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• 101150106931 IFNG gene Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 102100032818 Integrin alpha-4 Human genes 0.000 description 2
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
• 241000186660 Lactobacillus Species 0.000 description 2
• 241000222722 Leishmania <genus> Species 0.000 description 2
• 241000713666 Lentivirus Species 0.000 description 2
• 239000000232 Lipid Bilayer Substances 0.000 description 2
• 108090001030 Lipoproteins Proteins 0.000 description 2
• 102000004895 Lipoproteins Human genes 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 229930195725 Mannitol Natural products 0.000 description 2
• 241001467553 Mycobacterium africanum Species 0.000 description 2
• 241000186367 Mycobacterium avium Species 0.000 description 2
• 241001134667 Mycobacterium celatum Species 0.000 description 2
• 241000186365 Mycobacterium fortuitum Species 0.000 description 2
• 241001509451 Mycobacterium genavense Species 0.000 description 2
• 241001147828 Mycobacterium haemophilum Species 0.000 description 2
• 241000186364 Mycobacterium intracellulare Species 0.000 description 2
• 241000186363 Mycobacterium kansasii Species 0.000 description 2
• 241000187490 Mycobacterium scrofulaceum Species 0.000 description 2
• 241000187489 Mycobacterium simiae Species 0.000 description 2
• 101001057048 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) ESAT-6-like protein EsxB Proteins 0.000 description 2
• 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 2
• 108091061960 Naked DNA Proteins 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 102000005877 Peptide Initiation Factors Human genes 0.000 description 2
• 108010044843 Peptide Initiation Factors Proteins 0.000 description 2
• 108010004729 Phycoerythrin Proteins 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 229930189077 Rifamycin Natural products 0.000 description 2
• 241000714474 Rous sarcoma virus Species 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
• 241000256251 Spodoptera frugiperda Species 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 244000057717 Streptococcus lactis Species 0.000 description 2
• 235000014897 Streptococcus lactis Nutrition 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
• 108700012920 TNF Proteins 0.000 description 2
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
• 241000255985 Trichoplusia Species 0.000 description 2
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
• 108091023045 Untranslated Region Proteins 0.000 description 2
• IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 2
• UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
• ZWBTYMGEBZUQTK-PVLSIAFMSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate Chemical compound CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c4NC5(CCN(CC(C)C)CC5)N=c4c(=NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C ZWBTYMGEBZUQTK-PVLSIAFMSA-N 0.000 description 2
• FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 238000013019 agitation Methods 0.000 description 2
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
• 229940024545 aluminum hydroxide Drugs 0.000 description 2
• 102000005922 amidase Human genes 0.000 description 2
• 125000004103 aminoalkyl group Chemical group 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 230000030741 antigen processing and presentation Effects 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 239000012736 aqueous medium Substances 0.000 description 2
• 238000000429 assembly Methods 0.000 description 2
• 230000000712 assembly Effects 0.000 description 2
• 229960004099 azithromycin Drugs 0.000 description 2
• MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 238000004061 bleaching Methods 0.000 description 2
• 229910021538 borax Inorganic materials 0.000 description 2
• 229960005084 calcitriol Drugs 0.000 description 2
• GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
• 150000001720 carbohydrates Chemical class 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000022131 cell cycle Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 238000001516 cell proliferation assay Methods 0.000 description 2
• 210000004520 cell wall skeleton Anatomy 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000007958 cherry flavor Substances 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 230000002759 chromosomal effect Effects 0.000 description 2
• AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
• 229960002626 clarithromycin Drugs 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 239000012228 culture supernatant Substances 0.000 description 2
• 239000005547 deoxyribonucleotide Substances 0.000 description 2
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 239000003596 drug target Substances 0.000 description 2
• 239000002158 endotoxin Substances 0.000 description 2
• 108700004025 env Genes Proteins 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 238000013401 experimental design Methods 0.000 description 2
• 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 229940124307 fluoroquinolone Drugs 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 229940044627 gamma-interferon Drugs 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000030279 gene silencing Effects 0.000 description 2
• 238000001415 gene therapy Methods 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 229960003180 glutathione Drugs 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 238000002169 hydrotherapy Methods 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 230000002998 immunogenetic effect Effects 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000036512 infertility Effects 0.000 description 2
• 238000011081 inoculation Methods 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 229960003130 interferon gamma Drugs 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 210000003292 kidney cell Anatomy 0.000 description 2
• 229940039696 lactobacillus Drugs 0.000 description 2
• 230000003902 lesion Effects 0.000 description 2
• GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 239000000594 mannitol Substances 0.000 description 2
• 235000010355 mannitol Nutrition 0.000 description 2
• 238000002483 medication Methods 0.000 description 2
• 238000010197 meta-analysis Methods 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 101150014428 mpt64 gene Proteins 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 229960001699 ofloxacin Drugs 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 210000001539 phagocyte Anatomy 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 108700004029 pol Genes Proteins 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 235000007686 potassium Nutrition 0.000 description 2
• 230000001566 pro-viral effect Effects 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 238000011002 quantification Methods 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 230000000601 reactogenic effect Effects 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 230000002829 reductive effect Effects 0.000 description 2
• 230000002787 reinforcement Effects 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 125000002652 ribonucleotide group Chemical group 0.000 description 2
• 229960000885 rifabutin Drugs 0.000 description 2
• BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 2
• 229940081192 rifamycins Drugs 0.000 description 2
• WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 2
• 229960002599 rifapentine Drugs 0.000 description 2
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 229960001153 serine Drugs 0.000 description 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
• 235000020183 skimmed milk Nutrition 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 229910001415 sodium ion Inorganic materials 0.000 description 2
• 235000010339 sodium tetraborate Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 238000003756 stirring Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229940031626 subunit vaccine Drugs 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 239000000606 toothpaste Substances 0.000 description 2
• 229940034610 toothpaste Drugs 0.000 description 2
• 230000002103 transcriptional effect Effects 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 239000002691 unilamellar liposome Substances 0.000 description 2
• 230000006648 viral gene expression Effects 0.000 description 2
• 230000029812 viral genome replication Effects 0.000 description 2
• 238000011179 visual inspection Methods 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 1
• JPOKAKNGULMYHZ-UILVTTEASA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-3-(4-hydroxyp Chemical compound C([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=C(O)C=C1 JPOKAKNGULMYHZ-UILVTTEASA-N 0.000 description 1
• QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
• UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
• MUSGYEMSJUFFHT-UWABRSFTSA-N 2-[(4R,7S,10S,13S,19S,22S,25S,28S,31S,34R)-34-[[(2S,3S)-2-[[(2R)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanoyl]amino]-4-[[(2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl]-methylcarbamoyl]-25-(3-amino-3-oxopropyl)-7-(3-carbamimidamidopropyl)-10-(1H-imidazol-5-ylmethyl)-19-(1H-indol-3-ylmethyl)-13,17-dimethyl-28-[(1-methylindol-3-yl)methyl]-6,9,12,15,18,21,24,27,30,33-decaoxo-31-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29,32-decazacyclopentatriacont-22-yl]acetic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](N)Cc1ccc(O)cc1)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](C)NC(=O)CN(C)C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2cn(C)c3ccccc23)NC(=O)[C@@H](NC1=O)C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)C(N)=O MUSGYEMSJUFFHT-UWABRSFTSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
• 101150094949 APRT gene Proteins 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 206010067484 Adverse reaction Diseases 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108010025188 Alcohol oxidase Proteins 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 241000272525 Anas platyrhynchos Species 0.000 description 1
• 241000024188 Andala Species 0.000 description 1
• 241000272478 Aquila Species 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241001203868 Autographa californica Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 241000167854 Bourreria succulenta Species 0.000 description 1
• 108700031361 Brachyury Proteins 0.000 description 1
• OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
• 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 101100065968 Cereibacter sphaeroides fbp1 gene Proteins 0.000 description 1
• 101100012235 Cereibacter sphaeroides fbp2 gene Proteins 0.000 description 1
• 201000006082 Chickenpox Diseases 0.000 description 1
• 241000700114 Chinchillidae Species 0.000 description 1
• 229920001661 Chitosan Polymers 0.000 description 1
• VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 108091029430 CpG site Proteins 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 102100030497 Cytochrome c Human genes 0.000 description 1
• 108010075031 Cytochromes c Proteins 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 241000725618 Duck hepatitis B virus Species 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
• 241000991587 Enterovirus C Species 0.000 description 1
• 101710091045 Envelope protein Proteins 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 101100055028 Escherichia coli (strain K12) afuB gene Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 208000000666 Fowlpox Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 102000053187 Glucuronidase Human genes 0.000 description 1
• 108010060309 Glucuronidase Proteins 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 101710154606 Hemagglutinin Proteins 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
• 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010062717 Increased upper airway secretion Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 108090000176 Interleukin-13 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 102000000704 Interleukin-7 Human genes 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
• QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 241000186781 Listeria Species 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 208000032376 Lung infection Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
• 108010031099 Mannose Receptor Proteins 0.000 description 1
• 235000006679 Mentha X verticillata Nutrition 0.000 description 1
• 235000002899 Mentha suaveolens Nutrition 0.000 description 1
• 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
• 101100261636 Methanothermobacter marburgensis (strain ATCC BAA-927 / DSM 2133 / JCM 14651 / NBRC 100331 / OCM 82 / Marburg) trpB2 gene Proteins 0.000 description 1
• 241000018377 Methylococcaceae bacterium Species 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 241000204795 Muraena helena Species 0.000 description 1
• MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
• 241000238367 Mya arenaria Species 0.000 description 1
• 208000031998 Mycobacterium Infections Diseases 0.000 description 1
• 241000187488 Mycobacterium sp. Species 0.000 description 1
• 101100244718 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) PPE14 gene Proteins 0.000 description 1
• 101100377720 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) fbpA gene Proteins 0.000 description 1
• 101100054729 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) hspX gene Proteins 0.000 description 1
• 241000765897 Mycobacterium tuberculosis C Species 0.000 description 1
• 241000385073 Mycobacterium tuberculosis F11 Species 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 description 1
• KTHDTJVBEPMMGL-UHFFFAOYSA-N N-acetyl-L-alanine Natural products OC(=O)C(C)NC(C)=O KTHDTJVBEPMMGL-UHFFFAOYSA-N 0.000 description 1
• OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 241001028048 Nicola Species 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 101710176384 Peptide 1 Proteins 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 108010013639 Peptidoglycan Proteins 0.000 description 1
• 201000005702 Pertussis Diseases 0.000 description 1
• 101100124346 Photorhabdus laumondii subsp. laumondii (strain DSM 15139 / CIP 105565 / TT01) hisCD gene Proteins 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 241000243142 Porifera Species 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710176177 Protein A56 Proteins 0.000 description 1
• 101710188315 Protein X Proteins 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• 108020004518 RNA Probes Proteins 0.000 description 1
• 239000003391 RNA probe Substances 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 241000220010 Rhode Species 0.000 description 1
• 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 108010079723 Shiga Toxin Proteins 0.000 description 1
• 108010032838 Sialoglycoproteins Proteins 0.000 description 1
• 102000007365 Sialoglycoproteins Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 235000019892 Stellar Nutrition 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 241000906446 Theraps Species 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 102100036407 Thioredoxin Human genes 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010046980 Varicella Diseases 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 108010067390 Viral Proteins Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• UYRDHEJRPVSJFM-VSWVFQEASA-N [(1s,3r)-3-hydroxy-4-[(3e,5e,7e,9e,11z)-11-[4-[(e)-2-[(1r,3s,6s)-3-hydroxy-1,5,5-trimethyl-7-oxabicyclo[4.1.0]heptan-6-yl]ethenyl]-5-oxofuran-2-ylidene]-3,10-dimethylundeca-1,3,5,7,9-pentaenylidene]-3,5,5-trimethylcyclohexyl] acetate Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C=C\C=C(/C)\C=C/1C=C(\C=C\[C@]23[C@@](O2)(C)C[C@@H](O)CC3(C)C)C(=O)O\1 UYRDHEJRPVSJFM-VSWVFQEASA-N 0.000 description 1
• 239000003082 abrasive agent Substances 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 230000006838 adverse reaction Effects 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 239000007801 affinity label Substances 0.000 description 1
• 101150115889 al gene Proteins 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• 239000012637 allosteric effector Substances 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
• 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
• SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
• 210000001132 alveolar macrophage Anatomy 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 230000003698 anagen phase Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 235000010208 anthocyanin Nutrition 0.000 description 1
• 229930002877 anthocyanin Natural products 0.000 description 1
• 239000004410 anthocyanin Substances 0.000 description 1
• 150000004636 anthocyanins Chemical class 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000013011 aqueous formulation Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 230000005812 autoimmune toxicity Effects 0.000 description 1
• 230000007940 bacterial gene expression Effects 0.000 description 1
• 108010005774 beta-Galactosidase Proteins 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000008238 biochemical pathway Effects 0.000 description 1
• 238000003766 bioinformatics method Methods 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 229960002685 biotin Drugs 0.000 description 1
• 235000020958 biotin Nutrition 0.000 description 1
• 239000011616 biotin Substances 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
• JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• UHBYWPGGCSDKFX-UHFFFAOYSA-N carboxyglutamic acid Chemical compound OC(=O)C(N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-UHFFFAOYSA-N 0.000 description 1
• 230000021523 carboxylation Effects 0.000 description 1
• 238000006473 carboxylation reaction Methods 0.000 description 1
• 101150055766 cat gene Proteins 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 230000017455 cell-cell adhesion Effects 0.000 description 1
• 230000033383 cell-cell recognition Effects 0.000 description 1
• 108091092328 cellular RNA Proteins 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000007385 chemical modification Methods 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 235000019693 cherries Nutrition 0.000 description 1
• 238000011976 chest X-ray Methods 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 108091000085 chlorophyll binding Proteins 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 239000012539 chromatography resin Substances 0.000 description 1
• 229910052804 chromium Inorganic materials 0.000 description 1
• 239000011651 chromium Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 239000000084 colloidal system Substances 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 230000001010 compromised effect Effects 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 210000001787 dendrite Anatomy 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 241001493065 dsRNA viruses Species 0.000 description 1
• 238000004043 dyeing Methods 0.000 description 1
• 238000013399 early diagnosis Methods 0.000 description 1
• 230000000459 effect on growth Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 101150016690 esxA gene Proteins 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 210000001808 exosome Anatomy 0.000 description 1
• 101150028082 fbpA gene Proteins 0.000 description 1
• 101150082784 fbpB gene Proteins 0.000 description 1
• 210000004700 fetal blood Anatomy 0.000 description 1
• 239000012837 first-line chemotherapeutic agent Substances 0.000 description 1
• 239000004088 foaming agent Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 101150098622 gag gene Proteins 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 102000054766 genetic haplotypes Human genes 0.000 description 1
• 231100000025 genetic toxicology Toxicity 0.000 description 1
• 230000001738 genotoxic effect Effects 0.000 description 1
• 231100000734 genotoxic potential Toxicity 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 150000002314 glycerols Chemical class 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 229940029575 guanosine Drugs 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
• 230000002363 herbicidal effect Effects 0.000 description 1
• 239000004009 herbicide Substances 0.000 description 1
• 101150113423 hisD gene Proteins 0.000 description 1
• 239000012510 hollow fiber Substances 0.000 description 1
• 101150007644 hspX gene Proteins 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 230000028996 humoral immune response Effects 0.000 description 1
• 235000011167 hydrochloric acid Nutrition 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 238000001597 immobilized metal affinity chromatography Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 208000037798 influenza B Diseases 0.000 description 1
• 108700010900 influenza virus proteins Proteins 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 239000002054 inoculum Substances 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940100602 interleukin-5 Drugs 0.000 description 1
• 238000010212 intracellular staining Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007852 inverse PCR Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 229910052742 iron Inorganic materials 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 208000033353 latent tuberculosis infection Diseases 0.000 description 1
• 239000004816 latex Substances 0.000 description 1
• 229920000126 latex Polymers 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
• 230000029226 lipidation Effects 0.000 description 1
• 238000009630 liquid culture Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000004807 localization Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000005210 lymphoid organ Anatomy 0.000 description 1
• 210000003712 lysosome Anatomy 0.000 description 1
• 230000001868 lysosomic effect Effects 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000013507 mapping Methods 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• CSHFHJNMIMPJST-HOTGVXAUSA-N methyl (2s)-2-[[(2s)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoate Chemical compound NCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)OC)CC1=CC=CC=C1 CSHFHJNMIMPJST-HOTGVXAUSA-N 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
• LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 238000002887 multiple sequence alignment Methods 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
• 229950006780 n-acetylglucosamine Drugs 0.000 description 1
• 239000002077 nanosphere Substances 0.000 description 1
• 230000004719 natural immunity Effects 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 231100000957 no side effect Toxicity 0.000 description 1
• 238000007826 nucleic acid assay Methods 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229940100688 oral solution Drugs 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 239000007935 oral tablet Substances 0.000 description 1
• 239000007968 orange flavor Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 101800002712 p27 Proteins 0.000 description 1
• VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000011049 pearl Substances 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• UTIQDNPUHSAVDN-UHFFFAOYSA-N peridinin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC=CC=C2/OC(=O)C(=C2)C=CC34OC3(C)CC(O)CC4(C)C)C)C(C)(O)C1 UTIQDNPUHSAVDN-UHFFFAOYSA-N 0.000 description 1
• 230000007255 peripheral T cell response Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 210000000680 phagosome Anatomy 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 208000026435 phlegm Diseases 0.000 description 1
• 108010082527 phosphinothricin N-acetyltransferase Proteins 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 235000011007 phosphoric acid Nutrition 0.000 description 1
• 150000003016 phosphoric acids Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920002627 poly(phosphazenes) Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229920002851 polycationic polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
• 239000004810 polytetrafluoroethylene Substances 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 235000015497 potassium bicarbonate Nutrition 0.000 description 1
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
• 239000011736 potassium bicarbonate Substances 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 238000002953 preparative HPLC Methods 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000012913 prioritisation Methods 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000001902 propagating effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 150000003248 quinolines Chemical class 0.000 description 1
• 230000003439 radiotherapeutic effect Effects 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 101150066583 rep gene Proteins 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 125000006853 reporter group Chemical group 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 210000003660 reticulum Anatomy 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 238000013515 script Methods 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000002864 sequence alignment Methods 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• NTOCDDPMRUNYHP-UHFFFAOYSA-M sodium;2-(2,4,5-trichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC(Cl)=C(Cl)C=C1Cl NTOCDDPMRUNYHP-UHFFFAOYSA-M 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000012289 standard assay Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 230000004960 subcellular localization Effects 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 229940021747 therapeutic vaccine Drugs 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 108060008226 thioredoxin Proteins 0.000 description 1
• 229940094937 thioredoxin Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 230000003867 tiredness Effects 0.000 description 1
• 208000016255 tiredness Diseases 0.000 description 1
• 238000012090 tissue culture technique Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 101150081616 trpB gene Proteins 0.000 description 1
• 101150111232 trpB-1 gene Proteins 0.000 description 1
• 229960002109 tuberculosis vaccine Drugs 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 239000011882 ultra-fine particle Substances 0.000 description 1
• 210000003954 umbilical cord Anatomy 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000003501 vero cell Anatomy 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 239000000341 volatile oil Substances 0.000 description 1
• 235000012431 wafers Nutrition 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 208000016261 weight loss Diseases 0.000 description 1
• 239000009637 wintergreen oil Substances 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1